Pediatric Neuroblastoma Clinical Trials

Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma

This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigat...

Diagnosis: Pediatric Neuroblastoma

Phase: 1

Protocol Number: 14-494

Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer i...

Diagnosis: Pediatric Neuroblastoma

Phase: N/A

Protocol Number: 00-272

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treat...

Diagnosis: Pediatric Neuroblastoma

Phase:

Protocol Number: 14-449

Neuroblastoma Precision Trial

This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established m...

Diagnosis: Pediatric Neuroblastoma

Phase:

Protocol Number: 16-624

Study of Lorlatinib (PF-06463922)

Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in...

Diagnosis: Pediatric Brain Tumor, Pediatric Neuroblastoma

Phase:

Protocol Number: 17-393

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

This is a two arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles viru...

Diagnosis: Pediatric Neuroblastoma, Pediatric Brain Tumor

Phase:

Protocol Number: 17-103

A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or re...

Diagnosis: Pediatric Neuroblastoma, Pediatric Brain Tumor

Phase:

Protocol Number: 16-509

Testing the Addition of 131I-MIBG or Crizotinib to Intensive Therapy in People With High-risk Neuroblastoma (NBL)

This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblasto...

Diagnosis: Pediatric Neuroblastoma

Phase:

Protocol Number: 18-718

MIBG With Dinutuximab

131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease. In this pediatric phase 1 trial, 131I-MIBG w...

Diagnosis: Pediatric Neuroblastoma

Phase:

Protocol Number: 18-200